Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyCellularComponentnuclear body

RBM11 YLPM1 TCF20

3.82e-0390383GO:0016604
MousePhenoabnormal forebrain morphology

PRRC2B ITGA6 ALG13 TCF20

4.55e-04107264MP:0000783
MousePhenoincreased total body fat amount

YLPM1 ALG13 TCF20

5.18e-0442463MP:0010024
MousePhenodecreased bone mineral content

YLPM1 ALG13 TCF20

6.79e-0446563MP:0010124
MousePhenofailure to gastrulate

YLPM1 ALG13

1.05e-0311962MP:0001696
MousePhenoabnormal telencephalon development

ITGA6 TCF20

1.18e-0312662MP:0000934
MousePhenoabnormal cerebral hemisphere morphology

ITGA6 ALG13 TCF20

1.42e-0359963MP:0008540
MousePhenoabnormal bone mineral content

YLPM1 ALG13 TCF20

2.35e-0371363MP:0010122
Pubmed

Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation.

ITGA6 TCF20

8.78e-06208220564319
Pubmed

Proteomic and Biochemical Comparison of the Cellular Interaction Partners of Human VPS33A and VPS33B.

RBM11 PRRC2B ALG13

2.03e-052518329778605
Pubmed

Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner.

PRRC2B YLPM1 TCF20

2.46e-052688333640491
Pubmed

Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation.

PRRC2B YLPM1 TCF20

1.20e-044578332344865
Pubmed

Proteome-wide identification of HSP70/HSC70 chaperone clients in human cells.

RBM11 PRRC2B ITGA6 YLPM1

1.47e-0413678432687490
Pubmed

Human transcription factor protein interaction networks.

RBM11 PRRC2B YLPM1 TCF20

1.74e-0414298435140242
Pubmed

SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.

PRRC2B YLPM1 TCF20

2.07e-045498338280479
InteractionSMG7 interactions

RBM11 PRRC2B YLPM1 ALG13 TCF20

5.19e-0831985int:SMG7
InteractionSP7 interactions

RBM11 PRRC2B YLPM1 TCF20

3.39e-0630484int:SP7
InteractionALG13 interactions

PRRC2B ALG13 TCF20

3.99e-0518383int:ALG13
InteractionQKI interactions

RBM11 PRRC2B ALG13

4.46e-0519083int:QKI
InteractionVPS33A interactions

RBM11 PRRC2B ALG13

1.05e-0425383int:VPS33A
InteractionRBM20 interactions

PRRC2B ALG13

1.07e-044082int:RBM20
InteractionPRG2 interactions

ITGA6 MELK ALG13

1.49e-0428583int:PRG2
InteractionCELF1 interactions

PRRC2B YLPM1 ALG13

1.53e-0428883int:CELF1
InteractionFUBP3 interactions

PRRC2B YLPM1 ALG13

1.68e-0429783int:FUBP3
InteractionDTX2 interactions

RBM11 YLPM1 TCF20

2.29e-0433083int:DTX2
InteractionPCDHGA5 interactions

ITGA6 MELK

2.66e-046382int:PCDHGA5
InteractionPAIP2 interactions

PRRC2B ALG13

2.66e-046382int:PAIP2
InteractionTLE3 interactions

RBM11 ALG13 TCF20

3.37e-0437683int:TLE3
InteractionMKRN2 interactions

PRRC2B ITGA6 ALG13

3.61e-0438583int:MKRN2
InteractionPRRC2A interactions

RBM11 PRRC2B ALG13

3.72e-0438983int:PRRC2A
InteractionTXNL4A interactions

PRRC2B ALG13

3.97e-047782int:TXNL4A
InteractionR3HDM1 interactions

PRRC2B ALG13

4.73e-048482int:R3HDM1
InteractionNUP35 interactions

PRRC2B YLPM1 TCF20

4.79e-0442483int:NUP35
InteractionIRF4 interactions

PRRC2B TCF20

4.84e-048582int:IRF4
InteractionRNF43 interactions

PRRC2B ALG13 TCF20

4.89e-0442783int:RNF43
InteractionRERE interactions

PRRC2B ALG13

5.79e-049382int:RERE
InteractionDMRTB1 interactions

PRRC2B ALG13

5.92e-049482int:DMRTB1
InteractionCLEC11A interactions

PRRC2B TCF20

6.17e-049682int:CLEC11A
InteractionSPACA1 interactions

ITGA6 MELK

8.24e-0411182int:SPACA1
InteractionCD63 interactions

ITGA6 ALG13

8.69e-0411482int:CD63
InteractionFMR1 interactions

PRRC2B ALG13 TCF20

9.48e-0453683int:FMR1
InteractionSAMD4B interactions

PRRC2B ALG13

9.94e-0412282int:SAMD4B
InteractionEXOSC7 interactions

PRRC2B ALG13

1.08e-0312782int:EXOSC7
InteractionR3HDM2 interactions

PRRC2B ALG13

1.11e-0312982int:R3HDM2
InteractionPUM2 interactions

PRRC2B ALG13

1.38e-0314482int:PUM2
InteractionDAZL interactions

PRRC2B ALG13

1.40e-0314582int:DAZL
InteractionTCF20 interactions

ALG13 TCF20

1.42e-0314682int:TCF20
InteractionATXN1L interactions

PRRC2B ALG13

1.50e-0315082int:ATXN1L
InteractionCPEB4 interactions

PRRC2B ALG13

1.62e-0315682int:CPEB4
InteractionFBLN5 interactions

PRRC2B ALG13

1.68e-0315982int:FBLN5
InteractionNAGK interactions

PRRC2B YLPM1

1.74e-0316282int:NAGK
InteractionGARRE1 interactions

PRRC2B ALG13

1.85e-0316782int:GARRE1
InteractionRC3H1 interactions

PRRC2B MELK ALG13

1.86e-0367783int:RC3H1
InteractionCEP85 interactions

RBM11 PRRC2B

1.89e-0316982int:CEP85
InteractionZFP36 interactions

PRRC2B ALG13

2.17e-0318182int:ZFP36
InteractionATN1 interactions

PRRC2B ALG13

2.31e-0318782int:ATN1
InteractionSMAP2 interactions

PRRC2B ALG13

2.36e-0318982int:SMAP2
InteractionFAM120C interactions

PRRC2B ALG13

2.41e-0319182int:FAM120C
InteractionSIRT7 interactions

PRRC2B YLPM1 TCF20

2.44e-0374483int:SIRT7
InteractionKLF5 interactions

RBM11 PRRC2B

2.51e-0319582int:KLF5
InteractionLRP1 interactions

RBM11 MELK

2.54e-0319682int:LRP1
InteractionAGPS interactions

RBM11 PRRC2B

2.54e-0319682int:AGPS
InteractionSRGAP2 interactions

MELK YLPM1

2.56e-0319782int:SRGAP2
InteractionFEV interactions

PRRC2B TCF20

2.72e-0320382int:FEV
InteractionRBM47 interactions

PRRC2B ALG13

2.74e-0320482int:RBM47
InteractionTRIM66 interactions

PRRC2B ALG13

2.77e-0320582int:TRIM66
InteractionRBMS1 interactions

PRRC2B ALG13

2.82e-0320782int:RBMS1
InteractionPCGF1 interactions

YLPM1 ALG13

2.85e-0320882int:PCGF1
InteractionDAPK1 interactions

PRRC2B TAS2R60

2.88e-0320982int:DAPK1
InteractionTDRD3 interactions

PRRC2B ALG13

2.96e-0321282int:TDRD3
InteractionTLE1 interactions

PRRC2B ALG13

2.99e-0321382int:TLE1
InteractionZC3H7A interactions

PRRC2B ALG13

3.04e-0321582int:ZC3H7A
InteractionMEX3B interactions

PRRC2B ALG13

3.24e-0322282int:MEX3B
InteractionERG interactions

PRRC2B TCF20

3.27e-0322382int:ERG
InteractionBAG4 interactions

PRRC2B ALG13

3.30e-0322482int:BAG4
InteractionCNOT9 interactions

PRRC2B ALG13

3.50e-0323182int:CNOT9
InteractionMIA3 interactions

PRRC2B ALG13

3.50e-0323182int:MIA3
InteractionOTUD4 interactions

PRRC2B ALG13

3.65e-0323682int:OTUD4
CoexpressionBROWNE_HCMV_INFECTION_2HR_DN

ITGA6 YLPM1

9.13e-054882M521
CoexpressionZHANG_BREAST_CANCER_PROGENITORS_UP

ITGA6 MELK ALG13

2.37e-0443483M15150
CoexpressionZHANG_BREAST_CANCER_PROGENITORS_UP

ITGA6 MELK ALG13

2.61e-0444883MM1044
CoexpressionGSE2770_IL12_VS_TGFB_AND_IL12_TREATED_ACT_CD4_TCELL_2H_UP

PRRC2B TCF20

6.50e-0412882M6083
CoexpressionLI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_DN

PRRC2B MELK

1.06e-0316482M13108
CoexpressionBROWNE_HCMV_INFECTION_6HR_DN

ITGA6 YLPM1

1.06e-0316482M10311
CoexpressionGSE13946_CTRL_VS_DSS_COLITIS_GD_TCELL_FROM_COLON_DN

ITGA6 YLPM1

1.14e-0317082M2942
CoexpressionGSE45365_WT_VS_IFNAR_KO_CD11B_DC_MCMV_INFECTION_DN

RBM11 MELK

1.44e-0319182M9977
CoexpressionGSE45365_HEALTHY_VS_MCMV_INFECTION_CD11B_DC_IFNAR_KO_DN

RBM11 MELK

1.45e-0319282M9983
CoexpressionGSE17974_0.5H_VS_72H_UNTREATED_IN_VITRO_CD4_TCELL_UP

ITGA6 ALG13

1.48e-0319482M4234
CoexpressionGSE16450_IMMATURE_VS_MATURE_NEURON_CELL_LINE_UP

PRRC2B ITGA6

1.50e-0319582M7397
CoexpressionGSE17974_0.5H_VS_72H_IL4_AND_ANTI_IL12_ACT_CD4_TCELL_UP

ITGA6 ALG13

1.51e-0319682M4244
CoexpressionGSE17974_1H_VS_72H_UNTREATED_IN_VITRO_CD4_TCELL_UP

ITGA6 ALG13

1.53e-0319782M4237
CoexpressionGSE37301_COMMON_LYMPHOID_PROGENITOR_VS_GRAN_MONO_PROGENITOR_DN

PRRC2B ITGA6

1.53e-0319782M8871
CoexpressionGSE2585_THYMIC_MACROPHAGE_VS_MTEC_UP

PRRC2B TCF20

1.53e-0319782M6279
CoexpressionGSE1460_DP_THYMOCYTE_VS_NAIVE_CD4_TCELL_ADULT_BLOOD_DN

ITGA6 TCF20

1.53e-0319782M3465
CoexpressionGSE3982_EFF_MEMORY_CD4_TCELL_VS_TH2_UP

PRRC2B TCF20

1.54e-0319882M5580
CoexpressionGSE22886_UNSTIM_VS_STIM_MEMORY_TCELL_UP

ITGA6 TCF20

1.54e-0319882M4408
CoexpressionGSE11057_NAIVE_VS_EFF_MEMORY_CD4_TCELL_UP

RBM11 ITGA6

1.54e-0319882M3104
CoexpressionGSE13411_PLASMA_CELL_VS_MEMORY_BCELL_UP

ITGA6 MELK

1.54e-0319882M3253
CoexpressionGSE29949_MICROGLIA_VS_DC_BRAIN_UP

PRRC2B ALG13

1.56e-0319982M8399
CoexpressionGSE20727_H2O2_VS_ROS_INHIBITOR_TREATED_DC_UP

ITGA6 TCF20

1.56e-0319982M9255
CoexpressionGSE4142_NAIVE_BCELL_VS_PLASMA_CELL_UP

RBM11 PRRC2B

1.56e-0319982M6381
CoexpressionGSE8384_CTRL_VS_B_ABORTUS_4H_MAC_CELL_LINE_UP

ITGA6 MELK

1.56e-0319982M5753
CoexpressionGSE29618_PRE_VS_DAY7_POST_TIV_FLU_VACCINE_MDC_UP

PRRC2B YLPM1

1.56e-0319982M5009
CoexpressionGSE8621_UNSTIM_VS_LPS_PRIMED_AND_LPS_STIM_MACROPHAGE_UP

ITGA6 MELK

1.56e-0319982M6986
CoexpressionGSE22025_UNTREATED_VS_PROGESTERONE_TREATED_CD4_TCELL_DN

PRRC2B ALG13

1.57e-0320082M8384
CoexpressionGSE28726_ACT_CD4_TCELL_VS_ACT_VA24NEG_NKTCELL_DN

ITGA6 TCF20

1.57e-0320082M8306
CoexpressionGSE24726_WT_VS_E2_2_KO_PDC_UP

ITGA6 MELK

1.57e-0320082M8060
CoexpressionGSE25085_FETAL_LIVER_VS_ADULT_BM_SP4_THYMIC_IMPLANT_DN

RBM11 MELK

1.57e-0320082M8069
CoexpressionGSE19888_CTRL_VS_T_CELL_MEMBRANES_ACT_MAST_CELL_DN

ITGA6 TCF20

1.57e-0320082M7334
CoexpressionGSE10240_CTRL_VS_IL17_AND_IL22_STIM_PRIMARY_BRONCHIAL_EPITHELIAL_CELLS_UP

ITGA6 MELK

1.57e-0320082M303
CoexpressionGSE20366_TREG_VS_NAIVE_CD4_TCELL_HOMEOSTATIC_CONVERSION_UP

ITGA6 MELK

1.57e-0320082M4330
CoexpressionAtlasDevelopingGonad_e18.5_ovary_emap-12283_k-means-cluster#1_top-relative-expression-ranked_200

ITGA6 ALG13

1.45e-044982gudmap_developingGonad_e18.5_ovary_200_k1
CoexpressionAtlasdev gonad_e11.5_M_PrimGermCell_Oct_k-means-cluster#1_top-relative-expression-ranked_500

MELK ALG13

2.79e-046882gudmap_dev gonad_e11.5_M_PrimGermCell_Oct_k1_500
CoexpressionAtlasdev gonad_e11.5_F_PrimGermCell_Oct_k-means-cluster#3_top-relative-expression-ranked_500

MELK ALG13

3.13e-047282gudmap_dev gonad_e11.5_F_PrimGermCell_Oct_k3_500
CoexpressionAtlasDevelopingGonad_P2_ovary_emap-30224_k-means-cluster#3_top-relative-expression-ranked_500

ITGA6 ALG13

3.77e-047982gudmap_developingGonad_P2_ovary_500_k3
CoexpressionAtlasDevelopingGonad_e14.5_ ovary_emap-6699_k-means-cluster#5_top-relative-expression-ranked_500

ITGA6 ALG13

5.00e-049182gudmap_developingGonad_e14.5_ ovary_500_k5
CoexpressionAtlasdev gonad_e12.5_M_GermCellTestis_Oct_k-means-cluster#1_top-relative-expression-ranked_500

MELK ALG13

6.65e-0410582gudmap_dev gonad_e12.5_M_GermCellTestis_Oct_k1_500
CoexpressionAtlasdev gonad_e12.5_F_GermCellOvary_Oct_k-means-cluster#3_top-relative-expression-ranked_500

MELK ALG13

7.83e-0411482gudmap_dev gonad_e12.5_F_GermCellOvary_Oct_k3_500
CoexpressionAtlasDevelopingGonad_e18.5_ovary_emap-12283_k-means-cluster#1_top-relative-expression-ranked_500

ITGA6 ALG13

1.08e-0313482gudmap_developingGonad_e18.5_ovary_500_k1
CoexpressionAtlaskidney_e10.5_UretericTip_HoxB7_k-means-cluster#2_top-relative-expression-ranked_500

MELK ALG13

1.16e-0313982gudmap_kidney_e10.5_UretericTip_HoxB7_k2_500
CoexpressionAtlasDevelopingGonad_e18.5_ovary_emap-12283_top-relative-expression-ranked_200

ITGA6 ALG13

1.30e-0314782gudmap_developingGonad_e18.5_ovary_200
ToppCellrenal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Outer_Medullary_Collecting_Duct_Intercalated_Cell_Type_A|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

ITGA6 MELK

2.81e-0414482cc11cce43d1af8ac63140d05faf215ae9a10cde1
ToppCellmild_COVID-19_(asymptomatic)-CD8+_T_naive|World / disease group, cell group and cell class (v2)

RBM11 ITGA6

3.13e-0415282f944743f40ff6ed3a7a096dd53e12d3526c67c4d
ToppCellInt-URO-Lymphocyte-T_NK-CD8_Naive|Int-URO / Disease, Lineage and Cell Type

RBM11 ITGA6

3.13e-041528252d6f9cf1f4637c922f582705d625b4cbe3dc0c2
ToppCellmild_COVID-19_(asymptomatic)-CD8+_T_naive|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2)

RBM11 ITGA6

3.26e-0415582e2c901d5c9e42d25d7702e5e8fc19b06f7c817be
ToppCellmild_COVID-19_(asymptomatic)-CD4+_T_naive|World / disease group, cell group and cell class (v2)

RBM11 ITGA6

3.34e-041578223879e65a6acc33d9aad096cd23604a77b0ac9c2
ToppCelldroplet-Kidney-KIDNEY-30m-Lymphocytic-Epcam____proximal_tube_epithelial_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

YLPM1 ALG13

3.38e-04158821d78578dc1f8ba43dacdccae1082c0b9d749f64d
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_low-phase|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

RBM11 MELK

3.60e-04163822d6fd2562d78be9f83fa35d811eb7e27eb8cc5d1
ToppCellmild_COVID-19_(asymptomatic)-CD4+_T_naive|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2)

RBM11 ITGA6

3.78e-041678278d264af390bd89942ffbb2991dc94f50756d4c9
ToppCelldroplet-Kidney-KIDNEY-30m-Lymphocytic-Epcam____thick_ascending_tube_S_epithelial_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RBM11 MELK

4.34e-04179824166c4e1a8748a79ac6a11fd0b97c5344be2321b
ToppCelldroplet-Heart-4Chambers-18m-Neuronal-cardiac_neuron|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RBM11 ALG13

4.48e-04182826fdaf3c8c3952a8f14dd7288e523ed58eb1d3517
ToppCell10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-CD4_rest-C|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

ITGA6 TCF20

4.89e-041908269c5c4d5f4fb6e5ae2c9dbf9d209faf093c3f769
ToppCellPBMC-Severe-cDC_12|Severe / Compartment, Disease Groups and Clusters

ITGA6 MELK

4.89e-041908284ee185939bdefb10705b621a70da27701eadcee
ToppCell5'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Suprabasal-Suprabasal_L.0.0.1.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ITGA6 MELK

4.94e-04191820f9443da0f73d07456142fae08b2dc92a5b7b592
ToppCellsevere_COVID-19-CD4+_T_naive|World / disease group, cell group and cell class (v2)

RBM11 ITGA6

4.94e-041918255a282478488efd1561ea57a6f0218f55f711bb0
ToppCellPBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c05-FOS|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)

RBM11 ITGA6

4.99e-041928278546a6e077076834fd717607610ab6df3b6e7ba
ToppCell5'-GW_trimst-2-SmallIntestine-Endothelial-blood_vessel_EC-cycling_EC|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

ITGA6 MELK

5.04e-0419382dd443b83d328a9069ffe19ac3d74066e922515a5
ToppCell3'-Broncho-tracheal-Epithelial-Airway_epithelium-respiratory_basal_cell-Suprabasal-Suprabasal_L.0.0.2.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ITGA6 MELK

5.25e-04197822430f31d9312338e0ca23bfc6bdb0365340860fd
ToppCellfacs-Tongue-nan-3m-Epithelial-basal_cell_of_epidermis|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ITGA6 TCF20

5.30e-041988222559b161e67b49fe8028bfaf861e069063599f5
ToppCellSepsis-Int-URO-Lymphocyte-T/NK-CD8+_T_naive|Int-URO / Disease, condition lineage and cell class

RBM11 ITGA6

5.30e-04198828c7d00d8c27fb47954d8ac53eebc4582e92b970c
ToppCellSepsis-ICU-NoSEP-Lymphocyte-T/NK-CD4+_T_naive|ICU-NoSEP / Disease, condition lineage and cell class

RBM11 ITGA6

5.36e-04199824cb6faa6ea5d6d36b9969822f572f7a7b3855dad
ToppCellcontrol-unassigned|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

ITGA6 TCF20

5.36e-04199825db7c8089172ac8e796613b3cef618d87007a0ab
ToppCellLPS_anti-TNF-Endothelial-Endothelial-FOXM1|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

ITGA6 MELK

5.36e-041998298575fcce726589e93fbb4df1aab03e57cb56076
ToppCellLPS_IL1RA_TNF-Endothelial-Endothelial-FOXM1|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

ITGA6 MELK

5.41e-04200824cfe08878a6981bf7b3567f9e82192d8f060ddde
ToppCellTracheal-10x3prime_v2-Stromal-Peri/Epineurial_|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations

RBM11 ITGA6

5.41e-0420082f7c3a8f5ac156c05ad7335d6d142c154c7d86449
ToppCellTracheal-10x3prime_v2-Stromal-Peri/Epineurial_-NAF_epineurial|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations

RBM11 ITGA6

5.41e-042008224e13b6d9d2d8b29df1f02544ea9c50084d9e75c
DrugAntipyrine, 4-hydroxy [1672-63-5]; Up 200; 19.6uM; PC3; HG-U133A

PRRC2B YLPM1 ALG13

3.57e-05199831915_UP
DrugNSC 714187

ITGA6 TCF20

3.80e-048582CID005288693
DrugPhenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; PC3; HT_HG-U133A

ITGA6 YLPM1

1.63e-03177824652_DN
DrugCephaeline dihydrochloride heptahydrate [6487-30-5]; Down 200; 6uM; MCF7; HT_HG-U133A

PRRC2B ITGA6

1.69e-03180823290_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

ITGA6 YLPM1

1.82e-03187824302_DN
Drugcelastrol; Down 200; 2.5uM; MCF7; HT_HG-U133A_EA

PRRC2B ITGA6

1.82e-0318782887_DN
DrugPhthalic Acids

ITGA6 MELK ALG13

1.84e-0376283ctd:D010795
Drugresveratrol; Down 200; 50uM; MCF7; HG-U133A

MELK YLPM1

1.88e-0319082622_DN
DrugChlorpheniramine maleate [113-92-8]; Down 200; 10.2uM; PC3; HT_HG-U133A

PRRC2B YLPM1

1.90e-03191822055_DN
DrugRapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

PRRC2B ALG13

1.90e-03191821059_DN
Drugvinblastine sulfate; Up 200; 0.1uM; PC3; HT_HG-U133A

PRRC2B YLPM1

1.92e-03192827556_UP
Drug(+)-Isoproterenol (+)-bitartrate salt [14638-70-1]; Down 200; 11uM; HL60; HT_HG-U133A

YLPM1 ALG13

1.92e-03192823046_DN
DrugClotrimazole [23593-75-1]; Down 200; 11.6uM; HL60; HG-U133A

YLPM1 ALG13

1.94e-03193821549_DN
DrugRapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A

ITGA6 YLPM1

1.94e-03193826967_DN
DrugOmeprazole [73590-58-6]; Down 200; 11.6uM; MCF7; HT_HG-U133A

PRRC2B ITGA6

1.94e-03193824951_DN
DrugBetamethasone [378-44-9]; Down 200; 10.2uM; MCF7; HT_HG-U133A

ITGA6 ALG13

1.96e-03194825328_DN
DrugGalanthamine hydrobromide [1953-04-4]; Down 200; 10.8uM; MCF7; HT_HG-U133A

ITGA6 YLPM1

1.96e-03194824772_DN
DrugNifurtimox [23256-30-6]; Down 200; 14uM; MCF7; HT_HG-U133A

ITGA6 YLPM1

1.96e-03194824953_DN
Drugretinoic acid; Down 200; 1uM; PC3; HT_HG-U133A

PRRC2B YLPM1

1.96e-03194821211_DN
DrugTranexamic acid [1197-18-8]; Down 200; 25.4uM; HL60; HG-U133A

PRRC2B YLPM1

1.98e-03195821401_DN
DrugNaloxone hydrochloride [357-08-4]; Down 200; 11uM; HL60; HG-U133A

PRRC2B ALG13

1.98e-03195822006_DN
DrugHesperidin [520-26-3]; Up 200; 6.6uM; MCF7; HT_HG-U133A

ITGA6 YLPM1

1.98e-03195825313_UP
DrugST021200; Up 200; 10uM; PC3; HT_HG-U133A

PRRC2B YLPM1

1.98e-03195827559_UP
DrugSulfaphenazole [526-08-9]; Down 200; 12.8uM; HL60; HT_HG-U133A

PRRC2B YLPM1

1.98e-03195821836_DN
DrugMidodrine hydrochloride [3092-17-9]; Up 200; 13.8uM; PC3; HT_HG-U133A

PRRC2B ALG13

1.98e-03195822087_UP
DrugAzapropazone [13539-59-8]; Down 200; 13.4uM; MCF7; HT_HG-U133A

ITGA6 ALG13

1.98e-03195826522_DN
DrugScopolamin-N-oxide hydrobromide [6106-81-6]; Down 200; 10uM; PC3; HT_HG-U133A

PRRC2B YLPM1

2.00e-03196822099_DN
DrugCinnarizine [298-57-7]; Down 200; 10.8uM; HL60; HG-U133A

PRRC2B ALG13

2.00e-03196821558_DN
DrugCephalosporanic acid, 7-amino [957-68-6]; Down 200; 14.6uM; MCF7; HT_HG-U133A

PRRC2B YLPM1

2.00e-03196824826_DN
DrugClofazimine [2030-63-9]; Down 200; 8.4uM; HL60; HG-U133A

PRRC2B ALG13

2.00e-03196821624_DN
DrugBenzonatate [104-31-4]; Down 200; 6.6uM; HL60; HT_HG-U133A

PRRC2B ALG13

2.00e-03196821843_DN
Drug2-propylpentanoic acid; Up 200; 500uM; MCF7; HT_HG-U133A_EA

ITGA6 YLPM1

2.00e-03196821078_UP
DrugDosulepin hydrochloride [897-15-4]; Up 200; 12uM; HL60; HG-U133A

PRRC2B YLPM1

2.00e-03196821713_UP
DrugXylometazoline hydrochloride [1218-35-5]; Down 200; 14.2uM; HL60; HG-U133A

PRRC2B ALG13

2.00e-03196821423_DN
DrugNalbuphine hydrochloride [23277-43-2]; Up 200; 10.2uM; HL60; HG-U133A

PRRC2B YLPM1

2.00e-03196821379_UP
DrugBenzathine benzylpenicillin [5928-84-7]; Up 200; 4.2uM; HL60; HT_HG-U133A

YLPM1 ALG13

2.00e-03196822939_UP
DrugKetanserin tartrate hydrate [83846-83-7]; Down 200; 7uM; HL60; HG-U133A

YLPM1 ALG13

2.00e-03196821593_DN
DrugMifepristone [84371-65-3]; Down 200; 9.4uM; HL60; HG-U133A

YLPM1 ALG13

2.00e-03196821569_DN
DrugMephenesin [59-47-2]; Down 200; 22uM; PC3; HT_HG-U133A

PRRC2B YLPM1

2.02e-03197827374_DN
DrugBephenium hydroxynaphthoate [3818-50-6]; Down 200; 9uM; MCF7; HT_HG-U133A

ITGA6 YLPM1

2.02e-03197826466_DN
DrugTriamterene [396-01-0]; Down 200; 15.8uM; MCF7; HT_HG-U133A

PRRC2B YLPM1

2.02e-03197821697_DN
DrugYohimbine hydrochloride [65-19-0]; Down 200; 10.2uM; PC3; HT_HG-U133A

PRRC2B YLPM1

2.02e-03197827130_DN
DrugMonocrotaline [315-22-0]; Down 200; 12.2uM; HL60; HG-U133A

YLPM1 ALG13

2.02e-03197821757_DN
DrugViomycin sulfate [37883-00-4]; Up 200; 5.2uM; MCF7; HT_HG-U133A

ITGA6 ALG13

2.02e-03197827036_UP
DrugQuipazine dimaleate salt [4774-24-7]; Up 200; 9uM; HL60; HG-U133A

PRRC2B YLPM1

2.02e-03197821789_UP
Drugprochlorperazine dimaleate salt; Down 200; 10uM; PC3; HT_HG-U133A

PRRC2B YLPM1

2.02e-03197821215_DN
DrugSulpiride [15676-16-1]; Up 200; 11.8uM; PC3; HG-U133A

PRRC2B YLPM1

2.02e-03197821887_UP
DrugFlunixin meglumine [42461-84-7]; Down 200; 8.2uM; MCF7; HT_HG-U133A

PRRC2B YLPM1

2.02e-03197823411_DN
DrugThiorphan [76721-89-6]; Down 200; 15.8uM; MCF7; HT_HG-U133A

MELK ALG13

2.02e-03197822752_DN
DrugCyproheptadine hydrochloride [969-33-5]; Down 200; 12.4uM; PC3; HG-U133A

PRRC2B YLPM1

2.02e-03197821938_DN
DrugPropylthiouracil [51-52-5]; Down 200; 23.4uM; MCF7; HT_HG-U133A

PRRC2B ALG13

2.02e-03197822837_DN
DrugPralidoxime chloride [51-15-0]; Down 200; 23.2uM; MCF7; HT_HG-U133A

ITGA6 YLPM1

2.02e-03197826443_DN
DrugPhenylpropanolamine hydrochloride [154-41-6]; Down 200; 21.4uM; HL60; HG-U133A

PRRC2B ALG13

2.02e-03197821602_DN
DrugCarbinoxamine maleate salt [3505-38-2]; Down 200; 9.8uM; MCF7; HT_HG-U133A

PRRC2B YLPM1

2.04e-03198823466_DN
DrugProadifen hydrochloride [62-68-0]; Down 200; 10.2uM; PC3; HT_HG-U133A

PRRC2B ITGA6

2.04e-03198825807_DN
DrugMetformin hydrochloride [1115-70-4]; Down 200; 24.2uM; MCF7; HT_HG-U133A

PRRC2B YLPM1

2.04e-03198825487_DN
DrugPheniramine maleate [132-20-7]; Up 200; 11.2uM; PC3; HG-U133A

PRRC2B YLPM1

2.04e-03198821910_UP
DrugMolsidomine [25717-80-0]; Up 200; 16.6uM; HL60; HG-U133A

PRRC2B YLPM1

2.04e-03198821711_UP
DrugCinnarizine [298-57-7]; Down 200; 10.8uM; MCF7; HT_HG-U133A

PRRC2B ALG13

2.04e-03198827174_DN
DrugGBR 12909 dihydrochloride [67469-78-7]; Down 200; 7.6uM; HL60; HG-U133A

PRRC2B YLPM1

2.04e-03198821625_DN
DrugFluphenazine dihydrochloride [146-56-5]; Down 200; 7.8uM; PC3; HT_HG-U133A

PRRC2B ALG13

2.04e-03198825880_DN
DrugTolazoline hydrochloride [59-97-2]; Up 200; 20.4uM; PC3; HG-U133A

PRRC2B ALG13

2.04e-03198821918_UP
DrugPiracetam [7491-74-9]; Up 200; 28.2uM; HL60; HG-U133A

PRRC2B YLPM1

2.04e-03198821710_UP
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

PRRC2B ALG13

2.04e-03198823332_DN
DrugEthambutol dihydrochloride [1070-11-7]; Down 200; 14.4uM; PC3; HG-U133A

PRRC2B YLPM1

2.04e-03198821900_DN
DrugMeropenem [96036-03-2]; Down 200; 10.4uM; MCF7; HT_HG-U133A

PRRC2B YLPM1

2.04e-03198827180_DN
DrugGliquidone [33342-05-1]; Down 200; 7.6uM; MCF7; HT_HG-U133A

ITGA6 YLPM1

2.04e-03198826505_DN
DrugMethotrimeprazine maleat salt [7104-38-3]; Down 200; 9uM; PC3; HT_HG-U133A

PRRC2B YLPM1

2.04e-03198827399_DN
DrugAdrenosterone [382-45-6]; Up 200; 13.4uM; HL60; HT_HG-U133A

ITGA6 YLPM1

2.04e-03198823107_UP
DrugDizocilpine maleate [77086-22-7]; Down 200; 11.8uM; PC3; HT_HG-U133A

PRRC2B YLPM1

2.04e-03198822069_DN
DrugPyrantel tartrate [33401-94-4]; Down 200; 11.2uM; MCF7; HT_HG-U133A

PRRC2B ITGA6

2.06e-03199825513_DN
Drug(-)-Cinchonidine [485-71-2]; Up 200; 13.6uM; HL60; HG-U133A

YLPM1 ALG13

2.06e-03199821780_UP
DrugMethoxy-6-harmalan [3589-73-9]; Down 200; 18.6uM; PC3; HT_HG-U133A

PRRC2B YLPM1

2.06e-03199826355_DN
DrugMecamylamine hydrochloride [826-39-1]; Down 200; 19.6uM; PC3; HT_HG-U133A

YLPM1 ALG13

2.06e-03199827263_DN
Drughaloperidol; Down 200; 10uM; MCF7; HT_HG-U133A

PRRC2B ITGA6

2.06e-03199826963_DN
DrugTrichlorfon [52-68-6]; Up 200; 15.6uM; PC3; HT_HG-U133A

ITGA6 YLPM1

2.06e-03199821797_UP
DrugMedrysone [2668-66-8]; Down 200; 11.6uM; MCF7; HT_HG-U133A

PRRC2B YLPM1

2.06e-03199823403_DN
DrugTetrandrine [518-34-3]; Down 200; 6.4uM; PC3; HT_HG-U133A

PRRC2B YLPM1

2.06e-03199825821_DN
DrugProcainamide hydrochloride [614-39-1]; Down 200; 14.8uM; MCF7; HT_HG-U133A

PRRC2B ITGA6

2.06e-03199822618_DN
DrugCAY10397; Down 200; 10uM; MCF7; HT_HG-U133A

ITGA6 YLPM1

2.06e-03199827082_DN
DrugAmidopyrine [58-15-1]; Down 200; 17.2uM; HL60; HG-U133A

PRRC2B YLPM1

2.08e-03200821376_DN
DrugProadifen hydrochloride [62-68-0]; Down 200; 10.2uM; MCF7; HT_HG-U133A

ITGA6 ALG13

2.08e-03200827165_DN
DrugMeclofenoxate hydrochloride [3685-84-5]; Down 200; 13.6uM; MCF7; HT_HG-U133A

ITGA6 YLPM1

2.08e-03200823405_DN
DrugScopoletin [92-61-5]; Up 200; 20.8uM; HL60; HT_HG-U133A

ITGA6 YLPM1

2.08e-03200823131_UP
Diseasedepressive symptom measurement

YLPM1 TCF20

4.16e-0342672EFO_0007006
DiseaseIntellectual Disability

ALG13 TCF20

4.57e-0344772C3714756
Diseasebody fat percentage

PRRC2B YLPM1

5.43e-0348872EFO_0007800
DiseaseAlzheimer disease, polygenic risk score

MELK TCF20

7.74e-0358672EFO_0030082, MONDO_0004975
Diseaseattention deficit hyperactivity disorder, substance abuse, antisocial behaviour measurement

PRRC2B TCF20

1.41e-0280172EFO_0003888, EFO_0007052, MONDO_0002491

Protein segments in the cluster

PeptideGeneStartEntry
SYWHSMVYVPQMQQQ

ALG13

996

Q9NP73
FQKMQWHVYNPVLQL

RBM11

141

P57052
NLLNHPWIMQDYNYP

MELK

256

Q14680
YVYMNQQGRWNNVKP

ITGA6

391

P23229
MYQNYLRNHLQPWNV

TAS2R60

166

P59551
QQEQLYKMQHWQPVY

PRRC2B

636

Q5JSZ5
SQLHYKRQMYQQQPE

TCF20

1081

Q9UGU0
YEMQQQQFQHLYQEW

YLPM1

441

P49750